Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial.
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF, Nicholls SJ, Parkhomenko A, Averkov O, Brass N, Lutchmedial S, Malaga G, Damiani LP, Piegas LS, Granger CB, Goodman SG. Cantor WJ, et al. Among authors: nicolau jc. Am Heart J. 2022 Sep;251:1-12. doi: 10.1016/j.ahj.2022.05.005. Epub 2022 May 6. Am Heart J. 2022. PMID: 35533724 Clinical Trial.
Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction.
Llevadot J, Giugliano RP, Antman EM, Wilcox RG, Gurfinkel EP, Henry T, McCabe CH, Charlesworth A, Thompson S, Nicolau JC, Tebbe U, Sadowski Z, Braunwald E; InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Llevadot J, et al. Among authors: nicolau jc. Eur Heart J. 2001 Nov;22(22):2104-15. doi: 10.1053/euhj.2001.2622. Eur Heart J. 2001. PMID: 11686667 Clinical Trial.
[Guidelines of the Brazilian Cardiology Society on unstable angina and myocardial acute infarction without ST-segment elevation: Part I: Risk stratification and approaches in the first 12 hours after the patient arrives to the hospital].
Nicolau JC, Cesar LA, Timerman A, Piegas LS, Marin-Neto JA; Brazilian Cardiology Society. Nicolau JC, et al. Arq Bras Cardiol. 2001 Oct;77 Suppl 2:3-23. Arq Bras Cardiol. 2001. PMID: 11740595 Free article. Portuguese. No abstract available.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Among authors: nicolau jc. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW; COMPLY Investigators. Mahaffey KW, et al. Among authors: nicolau jc. Circulation. 2003 Sep 9;108(10):1176-83. doi: 10.1161/01.CIR.0000087404.53661.F8. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925455 Clinical Trial.
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rollins S, Theroux P, Ruzyllo W, Nicolau JC, Granger CB; CARDINAL Investigators. Patel MR, et al. Among authors: nicolau jc. Am J Cardiol. 2005 Mar 1;95(5):614-8. doi: 10.1016/j.amjcard.2004.11.008. Am J Cardiol. 2005. PMID: 15721102 Clinical Trial.
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Théroux P, et al. Among authors: nicolau jc. Eur Heart J. 2005 Oct;26(19):1964-70. doi: 10.1093/eurheartj/ehi292. Epub 2005 May 4. Eur Heart J. 2005. PMID: 15872036 Clinical Trial.
319 results